XM does not provide services to residents of the United States of America.
C
C

Cognizant

News

UnitedHealth tech unit's rivals say new, post-hack customers are staying

FOCUS-UnitedHealth tech unit's rivals say new, post-hack customers are staying By Leroy Leo and Sriparna Roy Sept 19 (Reuters) - Smaller rivals to UnitedHealth's UNH.N tech unit Change Healthcare say they are signing longer-term contracts with hospitals and other customers who had temporarily switched from the company after February's cyberattack shut down the unit's services.
C

Oracle shares pare gains as analysts weigh over $100 billion fiscal 2029 revenue forecast

UPDATE 1-Oracle shares pare gains as analysts weigh over $100 billion fiscal 2029 revenue forecast Shares rise 1.9% Oracle forecasts FY29 revenue to be $104 billion Raises fiscal 2026 revenue outlook Adds analyst comment in paragraphs 3 and 4, updates shares By Jaspreet Singh Sept 13 (Reuters) - Oracle ORCL.N shares pared most of their gains on Friday after spiking nearly 8%, with some analysts expressing reservations about the company's forecast of crossing $100 billion in revenue in fiscal 202
A
A
C
M
L

Oracle shares rise as it expects to cross $100 billion in fiscal 2029 sales

Oracle shares rise as it expects to cross $100 billion in fiscal 2029 sales Shares rise more than 6% in premarket trading Oracle forecasts FY29 revenue to be $104 billion Raises fiscal 2026 revenue outlook Sept 13 (Reuters) - Oracle ORCL.N shares rose more than 6% in premarket trading on Friday after the company said it expects to cross $100 billion in revenue in fiscal 2029, as the popularity of AI drives demand for its cloud services.
A
A
C
M
L

U.S. Constellation Energy, Eli Lilly, Talen Energy

U.S. RESEARCH ROUNDUP-Constellation Energy, Eli Lilly, Talen Energy Sept 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Eli Lilly and Talen Energy, on Friday. HIGHLIGHTS * Constellation Energy Corp CEG.O : Jefferies initiates with hold rating; target $183 * Eli Lilly LLY.N : JP Morgan raises target price to $1,100 from $1,050 * Moderna MRNA.O : JP Morgan cuts to underweight from neutral * Vo
A
C
C
F
F
H
H
H
I
K
W
F
D
T
Z
A
A
D
E
H
L

U.S. Broadcom, Costco Wholesale, Saia

U.S. RESEARCH ROUNDUP-Broadcom, Costco Wholesale, Saia Sept 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Broadcom, Costco Wholesale and Saia on Friday. HIGHLIGHTS * Broadcom Inc AVGO.O : JP Morgan raises target price to $210 from $200 * Costco Wholesale Corp COST.O : Oppenheimer raises target price to $955 from $925 * Globant SA GLOB.N : JP Morgan raises target price to $237 from $226 * Saia Inc SAIA.O : JP Morg
A
B
C
C
E
D
M
Z
C
F
I
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.